Loading
Aktis Oncology
Miniprotein alpha-radiopharmaceutical company; the first biotech IPO of 2026 (~$365M) funds Ac-225 programmes against Nectin-4 and B7-H3.
Overview
Aktis Oncology, based in Boston and listed as AKTS, is a miniprotein alpha-radiopharmaceutical company whose IPO, closed on 12 January 2026 for about 365 million dollars, was the first biotech IPO of the year and funds actinium-225 programmes against Nectin-4 and B7-H3. Its lead, 225Ac-AKY-1189 against Nectin-4, is in a US phase 1b; 225Ac-AKY-2519 against B7-H3 has an IND planned for the first half of 2026 after diagnostic imaging and dosimetry studies; an in-house cGMP radiopharmaceutical facility is due in the second half of 2026; and large pharma investors back it. OnCo links it to bladder, small-cell lung and prostate cancer, to targeted alpha therapy and alpha-emitter nanogenerators, and to Nectin-4 and B7-H3 as targets. Whether miniproteins can deliver alpha emitters safely is the open question. The targeted alpha therapy page carries the field.
Connected
11Similar pages
- CompanyUmoja Biopharma
Shares MPM BioImpact and the tag frontier.
- TechnologyBispecific ADC
Shares Nectin-4, B7-H3, Bladder & urothelial cancer and the tag frontier.
- TechnologyADC payload neutralisers
Shares Bladder & urothelial cancer and the tag frontier.
- TechnologyPhotothermal (plasmonic) nanoparticle ablation
Shares Prostate cancer and the tag frontier.
- TechnologyTrained innate immunity
Shares Bladder & urothelial cancer and the tag frontier.
- TechnologyMagnetic nanoparticle hyperthermia
Shares Prostate cancer and the tag frontier.
- CompanyGenerate:Biomedicines
Shares Bladder & urothelial cancer and the tag frontier.
- TechnologyRadio-antibody & radio-ADC
Shares Targeted alpha therapy and the tag frontier.
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
fiercebiotech.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-11 · Jude Gomila · Link orphan journals, startups, investors, collections an… · diff · file
Sourced, not expert-reviewed